Figure 4
From: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Effect of panobinostat on tumor growth in MDA-MB-231 and BT549 xenograft models. Female, CB-17/SCID mice (n = 5/group) were injected with (A) MDA-MB-231-tRFP or (B) BT-549-tRFP cells (5 × 106 cells/injection) bilaterally into the inguinal mammary fat pad. On day 14, mice were treated intraperitoneally (i.p.) with panobinostat (10 mg/kg) or vehicle (1:20 DMSO in normal saline) five days/week for 28 days. Data points represent average tumor volume ± SEM, (***, P < 0.001). DMSO, dimethyl sulfoxide; SEM, standard error of the mean; tRFP, turbo red fluorescent protein.